SBI, GeneFormatics Merger Mix Of Technologies, Drugs - And Cash

In these hard economic times, when you hear anybody in biotechnology say it's "not all about cash," you might suspect the speaker of being na ve or disingenuous. And when such words come out of the straitened genomics sector, they sound even much more suspicious. (BioWorld Financial Watch)